Potential Therapeutic Effects of MCC1274 on Alzheimer's Disease Pathologies in Mice.

We previously demonstrated that orally supplemented MCC1274 ( MCC1274) mitigated Alzheimer's disease (AD) pathologies in both 7-month-old mice and wild-type mice; thus, MCC1274 supplementation might potentially prevent the progression of AD. However, the possibility of using this probiotic as a treatment for AD remains unclear. Thus, we investigated the potential therapeutic effects of this probiotic on AD using 17-month-old mice with memory deficits and amyloid beta saturation in the brain. MCC1274 supplementation ameliorated memory impairment via an amyloid-cascade-independent pathway. It reduced hippocampal and cortical levels of phosphorylated extracellular signal-regulated kinase and c-Jun -terminal kinase as well as heat shock protein 90, which might have suppressed tau hyperphosphorylation and chronic stress. Moreover, MCC1274 supplementation increased hippocampal synaptic protein levels and upregulated neuronal activity. Thus, MCC1274 supplementation may alleviate cognitive dysfunction by reducing chronic stress and tau hyperphosphorylation, thereby enhancing both synaptic density and neuronal activity in 17-month-old mice. Overall, this study suggests that MCC1274 has anti-AD effects and can be used as a potential treatment for AD.